KRAS突变高级NSCLC:网络元分析和现实世界的证据的疗效和临床结果
Xiaoyu Gang1, Yige Sun1, Junli Hao1
1Department of Medical Oncology, The First Hospital of China Medical University, Shenyang 110001, China.
Lung cancer (Amsterdam, Netherlands)
|January 16, 2026
概括
免疫疗法是KRAS突变非小细胞肺癌 (NSCLC) 的关键. 单独或与化疗一起的PD-(L) 1抑制剂提供生存益处,特别是在一线治疗中,G12C抑制剂在后期阶段有效.
科学领域:
- 在瘤学瘤学.
- 翻译研究是翻译研究.
- 精准医学是一门精准的医学.
背景情况:
- 在非小细胞肺癌 (NSCLC) 中,KRAS突变很普遍.
- 针对KRAS突变NSCLC的治疗选择是具有挑战性的,因为异质性和缺乏向剂.
- 这项研究将网络元分析 (NMA) 与现实世界数据相结合,以指导精确处理.
研究的目的:
- 为了比较各种治疗方案对KRAS突变NSCLC的疗效.
- 通过结合NMA和现实世界的证据,为最佳治疗策略提供信息.
- 在KRAS突变NSCLC中确定治疗反应的预测生物标志物.
主要方法:
- 13个随机对照试验的贝叶斯网络元分析 (NMA).
- 对来自晚期KRAS突变NSCLC患者的现实数据的分析.
- 多变量分析以确定与无进展生存 (PFS) 相关的因素.
主要成果:
- 基于免疫疗法的疗法在KRAS突变NSCLC的治疗中通常表现优于化疗.
- 单独使用PD-(L) 1抑制剂的疗法显示出最高的整体存活期 (OS);化疗加PD-(L) 1抑制剂和抗血管生成疗法 (抗VEGF) 显示出最高的无进展存活期 (PFS).
- 现实世界的数据支持一线PD-(L) 1单疗法和化疗免疫疗法;KRAS G12C抑制剂在G12C突变NSCLC的后续线有效.
结论:
- 免疫疗法是KRAS突变NSCLC的第一线治疗的基石.
- 建议在选定的患者中使用PD-(L) 1单疗法,在更广泛的亚组中使用化疗免疫疗法.
- 克拉斯G12C抑制剂对于G12C突变NSCLC的后期治疗是有效的;对于非G12C疾病的选择仍然有限.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.6K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.6K
相关概念视频
01:21Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
01:24Kaplan-Meier Approach
577
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
577
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K